WuXi
NextCODE Selected as Genomics Platform for Singapore Precision Medicine Effort
Leading national stakeholders choose the global standard in
large-scale genomics to propel innovation in sequence-based digital health and
medicine in Singapore and Southeast Asia
- National Heart Centre Singapore (NHCS), together with SingHealth Duke-NUS Institute of Precision Medicine (PRISM) and Infocomm Media Development Authority (IMDA), spearheads vanguard population precision medicine program
- WuXi NextCODE to install massively scalable database, analytics and reporting suite at NHCS
- Pilot study aims to identify genetic risk factors and novel means to address heart disease risk
- WuXi NextCODE's cloud-based infrastructure will integrate seamlessly into digital health strategies and enable collaboration with other national genomics efforts around the world
- National Heart Centre Singapore (NHCS), together with SingHealth Duke-NUS Institute of Precision Medicine (PRISM) and Infocomm Media Development Authority (IMDA), spearheads vanguard population precision medicine program
- WuXi NextCODE to install massively scalable database, analytics and reporting suite at NHCS
- Pilot study aims to identify genetic risk factors and novel means to address heart disease risk
- WuXi NextCODE's cloud-based infrastructure will integrate seamlessly into digital health strategies and enable collaboration with other national genomics efforts around the world
NEWS
PROVIDED BY
Jan 05, 2017, 07:08 ET
SINGAPORE and SHANGHAI and CAMBRIDGE, Mass.
and REYKJAVIK, Iceland, Jan. 5, 2017 /PRNewswire/ -- WuXi
NextCODE, the contract genomics organization enabling precision
medicine worldwide, and the National Heart Centre Singapore (NHCS), a
leading national and regional cardiovascular medicine center, today announced
their partnership to advance population-based genomic research and precision
medicine applications in Singapore.
This marks an important first step in a national precision
medicine initiative that brings together NHCS as a leading research hospital in
cardiovascular disease, SingHealth Duke-NUS PRISM, as the institutional
flagship program on Precision Medicine, and the IMDA, as a part of its mission to advance Singapore's Smart
Nation vision. In addition to co-funding the project, IMDA scoped the
initiative's technical requirements. WuXi NextCODE was awarded by NHCS
following a competitive review of leading global genomics platforms.
Under the partnership, WuXi NextCODE will create an
instantly queriable cloud-based enterprise data warehouse integrating
large-scale whole genome sequence, medical and wearables data from both
cardiovascular patients and healthy control subjects recruited by NHCS. This
proof-of-concept resource will power research into novel genetic risk factors
for heart disease in the Singapore and Southeast Asia populations
more broadly. It will also enable the generation of clinical reports offering
actionable insights on different types of genetic risk, carrier status and drug
response, with the aim of informing personalized health and wellness. The
partnership contemplates expanding from heart disease into other disease types,
and WuXi NextCODE's infrastructure is scalable to hundreds of thousands of
participants.
"We are honored to be chosen by such visionary partners
to innovate cutting-edge precision medicine in Singapore," said
Hannes Smarason, COO of WuXi NextCODE. "We are the backbone for leading
precision medicine projects in the US, Europe, China and the Middle
East, and Singapore's leadership in digital convergence and
healthcare provides a unique opportunity to advance our technology in new ways
to benefit patients and people here and across the region."
"NHCS is delighted to partner with IMDA and WuXi
NextCODE in this pilot project," commented Associate Professor Yeo
Khung Keong, Senior Consultant, Department of Cardiology, National Heart Centre
Singapore. "We believe that the scientific and technical expertise that
WuXi NextCODE provides will enable us to integrate precision medicine into
clinical care and medical research. I am very much looking forward to this
collaboration."
"IMDA seeks to enhance Singapore's technology
capabilities through the use of infocomm media to improve the lives of citizens
and enhance businesses. Our collaboration with partners such as WuXi NextCODE
in bioinformatics is one example of using Singapore as a testbed to
develop new innovative technological solutions that bring significant benefits
and create high value-added jobs and businesses for ICM professionals in the
health and pharmaceutical industries. Creating and applying new infocomm
media technologies in healthcare and wellness is an important aspect of Singapore's Smart
Nation journey," said Mr Khoong Hock Yun, Assistant Chief Executive
(Development), IMDA.
沒有留言:
發佈留言